Theranexus (EPA:ALTHX) | Finanzwire

Basculer en Français

10109	Companies
207175	Keywords
137297	Articles
109801	Press releases

Home
Companies
Theranexus

BRIEF

published on 09/26/2024 at 18:05, 1 year 6 months ago

Theranexus announces its financial results for the first half of 2024

Financial Results Cost Reduction Biopharmaceutical Theranexus Batten-1
PRESS RELEASE

published on 09/26/2024 at 18:00, 1 year 6 months ago

THERANEXUS ANNOUNCES FIRST HALF 2024 FINANCIAL RESULTS
Theranexus reports cost reduction success and positive first half 2024 financial results, led by completion of Batten-1 clinical trial and operating grants

Financial Results Cost Reduction Clinical Trial Theranexus Batten-1
BRIEF

published on 07/11/2024 at 18:50, 1 year 8 months ago

Theranexus announces its cash flow as of June 30, 2024 and details the progress of Batten-1

Treasury Funding Theranexus Batten-1 Neurological Disease
PRESS RELEASE

published on 07/11/2024 at 18:45, 1 year 8 months ago

Theranexus publishes its cash position as of 30 June 2024 and presents an update on the progress of Batten-1
Biopharmaceutical company Theranexus announces implementation of new equity line to finance Phase III trial for Batten-1 drug in juvenile Batten disease. Update on Batten-1 program included

Biopharmaceutical Company Phase III Trial Theranexus Batten-1 Equity Line
BRIEF

published on 07/03/2024 at 07:35, 1 year 8 months ago

Theranexus, CRNL and CERMEP winners of the Auvergne-Rhône-Alpes “Research Pact 2024” project

Research Neurology Auvergne-Rhône-Alpes Theranexus Neuroimaging
PRESS RELEASE

published on 07/03/2024 at 07:30, 1 year 8 months ago

THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE "2024 RESEARCH PACT" PROJECT FOR THE AUVERGNE-RHÔNE-ALPES REGION
Theranexus, Lyon Neuroscience Research Center, and CERMEP win research pact project 'IMASO' in Auvergne-Rhône-Alpes Region for preclinical neuroimaging in rare neurological diseases

Theranexus Neurological Diseases Research Pact Auvergne-Rhône-Alpes Region Preclinical Neuroimaging
BRIEF

published on 06/06/2024 at 07:35, 1 year 9 months ago

Theranexus and BBDF Announce Positive Results at 18 Months for Batten-1 in Phase 1/2 Study

Theranexus Batten-1 BBDF Batten Disease Neurofilaments
PRESS RELEASE

published on 06/06/2024 at 07:30, 1 year 9 months ago

Theranexus and BBDF confirm positive 18-month results for Batten-1 in Phase I/II trial based on neurofilaments, a biomarker of neuronal death
Theranexus and BBDF confirm positive results in Phase I/II trial evaluating Batten-1 drug for CLN3 Batten disease after 18 months of treatment, showing decline in NfL biomarker levels and therapeutic potential

Theranexus Batten-1 BBDF CLN3 Batten Disease Neurofilament Light Chains
BRIEF

published on 05/02/2024 at 07:35, 1 year 10 months ago

Theranexus unveils its universal registration document for 2023

2023 Biopharmaceutical Universal Registration Document Theranexus Rare Neurological Diseases
BRIEF

published on 04/29/2024 at 18:25, 1 year 11 months ago

Theranexus Reports 2023 Full-Year Results and Details Recent Progress

2023 Financial Results Theranexus Rare Neurological Diseases PickASO Project Batten Disease

Accesswire

Published on 03/30/2026 at 00:15, 1 hour 50 minutes ago

$520,000 Cash R&D Tax Refund Received
Published on 03/29/2026 at 12:15, 13 hours 50 minutes ago

China Xlx Announces 2025 Annual Results Deepening Efforts in Reducing Costs, Enhancing Efficiency, Strengthening Competitiveness Through Differentiation and Driving Marketing Transformation
Published on 03/28/2026 at 01:00, 2 days 1 hour ago

Battery X Metals Announces Confidential Submission of Amended Draft Registration Statement with the U.S. Securities and Exchange Commission in Connection with Proposed U.S. National Securities Exchange Initial Public Offering
Published on 03/28/2026 at 00:55, 2 days 1 hour ago

Notification of Relevant Change to Significant Shareholder
Published on 03/28/2026 at 00:50, 2 days 1 hour ago

"Rise" Selected as NASA Artemis II Moon Mascot

View all ACCESSWIRE

EQS Group

Published on 03/29/2026 at 17:05, 9 hours ago

FAST III trial demonstrates non-inferiority of CAAS vFFR to invasive wire-based FFR
Published on 03/28/2026 at 10:05, 1 day 16 hours ago

Hisense Advances a Quiet Green Revolution in Home Entertainment
Published on 03/28/2026 at 08:56, 1 day 17 hours ago

Turkiye Garanti Bankasi A.S.: Sale of Garanti Bank S.A. and our public disclosure dated 10.03.2026
Published on 03/28/2026 at 01:42, 2 days ago

EQS-Adhoc: Raiffeisen Bank International AG: Agreement on the acquisition of Garanti BBVA Group Romania
Published on 03/27/2026 at 21:58, 2 days 4 hours ago

Kaufman & Broad SA: Availability of the Universal Registration Document 2025

Les Echos

Published on 03/27/2026 at 19:06, 2 days 6 hours ago

Mersen: Disclosure of trading own shares
Published on 03/27/2026 at 18:52, 2 days 7 hours ago

Crédit Agricole CIB announces the publication of its 2025 Universal Registration Document
Published on 03/27/2026 at 18:40, 2 days 7 hours ago

2026 share capital increase reserved for members of the Saint-Gobain Group employee savings plan
Published on 03/27/2026 at 17:53, 2 days 8 hours ago

Publication of Carrefour's 2025 Universal Registration Document
Published on 03/27/2026 at 17:45, 2 days 8 hours ago

PUBLICATION OF THE UNIVERSAL REGISTRATION DOCUMENT FISCAL YEAR 2025

View all LES ECHOS COMFI WIRE